Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Brooke Brander (NPI 1083838239)

Field	Value
Entity Type	Individual
Organization	Brooke Brander
Address	3232 N Northhills Blvd
City	Fayetteville
State	AR
ZIP	72703
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 12, 2007

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

BROOKE BRANDER’s billing footprint is essentially Medicare-only: Total Medicare revenue: $2.1M while Total Medicaid revenue: none (no Medicaid billing on file). This makes the provider effectively single-payer in the available data and limits comparative insights into Medicaid-facing service lines or volume in Arkansas.

Revenue is highly concentrated in a small set of infused and biologic therapies: the precomputed top 3 Medicare codes by revenue account for 56.0% of this provider's total Medicare revenue. Those top contributors are J9271 ($524.6K, 26.8%), J1561 ($336.6K, 17.2%), and J9144 ($232.6K, 11.9%), indicating that a majority of dollars flow from drug administration rather than routine E/M or ancillary testing.

The code mix and highest-dollar items point to an oncology/infusion operation focused on high-cost immunotherapies and biologics. High-revenue drugs appearing near the top of the list include J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab), complemented by chemotherapy administration codes such as 96413 and infusion initiation 96365, which together suggest in-office infusion as a core service.

Competitive standing across the top drug codes is mixed: J1561 ranks #35 of 180 (81th percentile) and therefore shows relatively elevated national placement for that immune globulin product even while the file characterizes its volume as typical; by contrast J9271 ranks #930 of 1841 (49th percentile) and J9144 ranks #421 of 615 (30th percentile), both described in the data as typical or modest volume for those agents. This pattern implies pockets of above-average concentration on particular biologics amid otherwise typical national participation for other oncology drugs.

Non-drug services show notable outpatient throughput: 99214 contributes $78.9K (4.0%) and ranks #14194 of 479517 (97th percentile), which the data flags as notably above typical national volume for that E/M code. Imaging and advanced diagnostics are also meaningful — 74178 accounts for $23.6K (1.2%) and ranks #316 of 11397 (97th percentile; notably above typical national volume) — supporting a practice that pairs therapeutic infusions with frequent imaging and follow-up management.

High-volume laboratory and supportive-care items further support an active oncology clinic workflow: 80053 ($15.8K) and 85025 ($13.5K) appear with high national placements (80053 ranks #832 of 26416, 97th percentile; 85025 ranks #1231 of 32833, 96th percentile) and many chemistry/hematology panels (83735, 83615, 84100, 82248) are regularly billed. These lab patterns are consistent with routine monitoring of systemic cancer therapies and supportive care such as growth factor use (Q5108) and epoetin (J0885).

Provider tenure is long in the Medicare dataset — NPI enumerated 2007-04-12 (~19 years ago) — which, combined with the $2.1M Medicare-only revenue base, suggests an established oncology practice focused on the Medicare population rather than on Medicaid. That longevity may reflect stable referral relationships for cancer care and infusion services within the local market.

Operational and payer implications: the absence of Medicaid billing (none (no Medicaid billing on file)) means the provider has limited Medicaid exposure and contracting leverage on that payer, while the heavy dependence on a handful of high-cost drugs (56.0% of Medicare revenue concentrated in the top three codes) could create revenue sensitivity to formulary, reimbursement, or site-of-care changes affecting those specific agents. Analysts should treat this profile as a Medicare-centric infusion/oncology practice with specific strengths in certain biologics and comparatively elevated utilization of E/M and imaging services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

105 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	12,200	$40	$524.6K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	8,860	$40	$336.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,120	$40	$232.6K
J9299	Injection, nivolumab, 1 mg	8,660	$20	$207.8K
J0897	Injection, denosumab, 1 mg	6,840	$20	$123.1K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	110	$1,010	$108.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	920	$90	$78.9K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	1,980	$30	$67.2K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,280	$30	$39.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	380	$90	$33.4K

Showing 1–10 of 105

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 105 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Brooke Brander — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

105 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	34	40	20,700	$40	$896.3K
J0129	16	20	8,960	$30	$532.4K
J9299	26	30	15,660	$20	$432.9K
J9144	10	10	10,530	$40	$361.9K
J1561	1	10	5,930	$40	$216.4K
J1745	9	10	3,150	$30	$102.3K
Q5115	19	20	2,800	$30	$95.9K
J0897	36	160	2,580	$20	$89.7K
78815	46	100	90	$550	$83.7K
J0885	33	40	4,070	$10	$38K

Showing 1–10 of 105

Related Providers

Other providers that share a Tax Identification Number (TIN) with Brooke Brander, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Brooke Brander, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sanders, Tompkins, Schiro, Landers And Sanders PLLC	AR	Pediatric Dentistry	$0	$30.4M
Children's Therapy Services, Inc.	AR	Pediatric Physical Therapist	$0	$29.2M
Life Styles Inc.	AR	Case Management Agency	$0	$19.6M
Washington Regional Medical Center	AR	General Acute Care Hospital	$0	$10.9M
Cross Therapy Services, Ltd	AR	Pediatric Occupational Therapist	$0	$5.8M
Medical Associates Of Northwest Arkansas PA	AR	Pediatrics Physician	$0	$5.8M
Oral & Facial Surgery Center PA	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.8M
Thomas A. Sarna, Dds PLLC	AR	Oral and Maxillofacial Surgery Clinic/Center	$0	$3.4M
Washington Regional Medical System	AR	Hospitalist Physician	$0	$3.4M
The Therapy Spot,llc	AR	Speech-Language Pathologist	$0	$3.2M

Brooke Brander — Billing Profile & Reimbursement Data

Sign up for Brooke Brander — Billing Profile & Reimbursement Data policy alerts

Brooke Brander — Billing Profile & Reimbursement Data

Sign up for Brooke Brander — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References